Is the critical pathway effective for the treatment of gastric cancer? by Jeong, Sang-Ho et al.
ORIGINAL ARTICLE
Copyright © 2011, the Korean Surgical Society
J Korean Surg Soc 2011;81:96-103
DOI: 10.4174/jkss.2011.81.2.96 JKSS
Journal of the Korean Surgical Society
pISSN 2233-7903ㆍeISSN 2093-0488
Received October 6, 2010, Accepted June 9, 2011
Correspondence to: Han-Kwang Yang
Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, 28 Yeongeon-dong, Jongno-gu, Seoul 
110-799, Korea
Tel: ＋82-2-2072-3797, Fax: ＋82-2-3672-0042, E-mail: hkyangsnu@gmail.com
*Recently moved to the Department of Surgery, Gyeongsang National University Hospital, Jinju, Korea
cc  Journal of the Korean Surgical Society is an Open Access Journal. All articles are distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Is the critical pathway effective for the treatment of 
gastric cancer?
Sang-Ho Jeong
1,*, Moon-Won Yoo
2, Hong-Man Yoon
1, Hyuk-Joon Lee
1,3, Hye Sung Ahn
1, 
Jae-Jin Cho
1, Hyung-Ho Kim
1, Kuhn-Uk Lee
1, Han-Kwang Yang
1,3
1Department of Surgery, Seoul National University College of Medicine, 
2Department of Surgery, Konkuk University Hospital, 
3Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
Purpose: The present study was conducted to investigate the low compliance rate of the critical pathway (CP) and whether 
CP is effective for treatment of gastric cancer in radical gastrectomy. Methods: The medical records of 631 patients who had 
undergone radical gastrectomy with D2 lymph node dissection were reviewed. This study compared data from patients in 
early gastric cancer (EGC) and advanced gastric cancer (AGC) groups, which were further subdivided into general care 
(non-CP) and CP groups. Results: The mean length of preoperative hospital stays were significantly different between the 
EGC and AGC patients (P ＜  0.05). However, there was no difference in the mean length of postoperative hospital stays be-
tween non-CP and CP groups among either EGC patients or AGC patients (P ＞  0.05). The postoperative and total cost of hos-
pitalization was not statistically different between either of the groups (P ＞  0.05); however, the mean preoperative costs were 
significantly different (P ＜  0.05). Conclusion: We conclude that use of the CP following gastrectomy is unnecessary. To de-
crease the length of hospital stay and associated costs, preoperative examination and consultation should be performed be-
fore admission.
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INTRODUCTION
The critical pathway (CP), also known as the clinical 
path or pathway, is a set of guidelines for patient care that 
outlines the objectives of the patient care plan along with 
the corresponding ideal sequence and timing of physician 
and staff action for achieving these goals with optimal effi-
ciency [1,2]. The use of the CP is intended to allow for the 
standardization of patient management, as well as im-
prove the quality and efficiency of patient care. The term 
‘clinical pathway’ was coined in 1985 by Zander et al. at the 
New England Medical Center. The CP is used for the treat-
ment of many medical conditions across the continuum of 
care [3-5]. Some studies have found that the critical path-
ways can lead to a decrease in postoperative length of stay 
and hospital charges, such as in colorectal [6,7], liver [8], 
vascular [9,10], obstetric [11], urologic [12,13], and pedia-
tric procedures [14].Critical pathway for gastric cancer
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The CP was first implemented at Our Hospital in 
September 2004, and the first use of electric medical record 
(EMR)-based CP was for the management of cataract sur-
gery patients in the Department of Ophthalmology in 
August 2005. Since then, six CPs have been developed at 
the Department of Surgery for use in the treatment of 
stomach cancer, breast cancer, thyroid diseases and be-
nign gallbladder diseases. The CPs that were developed 
include procedures such as gastrectomy, routine mastec-
tomy, mastectomy with neoadjuvant chemotherapy, total 
thyroidectomy, subtotal thyroidectomy and laparoscopic 
cholecystectomy. Additionally, EMR-based critical path-
ways were developed and applied in July 2006 to provide 
care for patients following gastrectomy for gastric cancer. 
However, compliance with the CP developed for treat-
ment of stomach cancer was lower than for other diseases. 
Therefore, we investigated the low compliance rate of the 
CP for stomach cancer and analyzed the effectiveness of 
the CP for reducing the length of hospital stay and asso-
ciated care costs. 
METHODS
The medical records of 631 consecutive patients who 
had undergone radical gastrectomy with D2 lymph node 
dissection between December 1st, 2006 and November 
30th, 2007 were reviewed. This included patient character-
istics and data from hospital records (sex, age, length of 
hospital stay and tumor, node, metastasis [TNM] stages), 
as well as information on the specific operative methods 
used (resection, combined resection and reconstruction). 
The patients were divided into early gastric cancer (EGC) 
and advanced gastric cancer (AGC) groups for data com-
parison, based on differences between the two groups in 
the range of lymph node dissection, length of post-
operative hospital stay and postoperative complications. 
Each group was further subdivided into a general care 
(non-CP) group and a critical pathway (CP) group.
To compare the effects of application of the CP to the 
management of different cases, four diseases were ana-
lyzed: stomach cancer, breast cancer, thyroid disease and 
benign gallbladder disease. The analysis included 495 cas-
es of mastectomy, 322 cases of thyroidectomy, 371 cases of 
laparoscopic cholecystectomy, and 380 cases of gas-
trectomy during the period between May and September 
of 2007. 
Inclusion and exclusion criteria for CP
Patients included in the study were those diagnosed 
with gastric adenocarcinoma and those with potentially 
curative diseases. Exclusion criteria were laparoscopic 
surgery, emergency surgery, concomitant malignancies, 
palliative surgery, severe comorbidities, and severe mal-
nutrition (American Society of Anesthesiologists grading 
grades 4).
Perioperative management of radical gastrectomy 
for gastric cancer
Non-CP groups
Patients were admitted three to four days before 
surgery. Preoperative laboratory tests and diagnostic mo-
dalities (endoscopy and computed tomography [CT] scan) 
were performed in the outpatient clinic. After the patients 
were admitted, the presence of concomitant diseases was 
assessed and consultation for operative safety was 
obtained. The patients underwent bowel preparation at 
preoperative day one, and antibiotics (intravenous Cefa-
zolin and Gentamicin) were administered before surgery 
and on the first postoperative day. The nasogastric tube 
was removed when the patient passed flatus and began 
taking sips of water. In the absence of complications after 
the ingestion of water, the patients were started on a 
semi-fluid diet. The patients were maintained on a semi- 
fluid diet for a minimum of two days, after which time 
they were placed on a soft brand diet. The closed suction 
drain was removed after water was ingested without 
complications. After confirmation in the pathology report, 
the patients were discharged from the hospital.
CP groups
Patients were assessed using preoperative laboratory 
tests and diagnostic modalities (endoscopy and CT scan); 
concomitant diseases were also investigated and con-
sultation for operative safety was obtained at the out-Sang-Ho Jeong, et al.
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Fig. 1. Critical pathway for hospital staff. HD, hospital day; Pre-op, preoperative; OP, operation; e’, electrolyte; X matching for Tf, cross 
matching for transfusion; CBC, complete blood cell count; CPA, Chest PA; v/s, vital sign; Bwt, body weight ; Ht, height; I/O, input and output; 
L-tube, levin tube; PCA, patient controlled analgesia; W/A, ward ambulation; BR, bed rest; SFP, semi-Fowlers position; A/C, active cough; 
D/B, deep breathing.
patient clinic before admission. The patients were admit-
ted two days before surgery, at which time the operative 
safety was checked again. Following surgery, the nasogas-
tric tube was removed on the first postoperative day, and 
sips of water were administered to the patients on the third 
postoperative day irrespective of passing flatus. If water 
was ingested without complication, the patients were 
started early on a semi-fluid diet on the fourth post-
operative day, and the closed suction drain was removed. 
In the absence of specific complications or complaints, the 
patients were discharged from the hospital on the seventh 
to eighth postoperative day (Figs. 1, 2). 
Surgical procedure
All cases underwent either a radical subtotal gas-
trectomy with gastroduodenostomy (Billroth I) or a gas-
trojejunostomy (Billroth II). Roux-en-Y esophagojeju-
nostomy with or without a Paulino pouch was performed 
after total gastrectomy. D2 lymph node dissection with cu-
rative intent was performed on all patients [15]. For tu-Critical pathway for gastric cancer
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Fig. 2. Critical pathway for patient.
mors located in the lower third of the stomach, the dou-
ble-stapling Billroth I method was used [16]. However, if 
the tumor extended to the upper part of the stomach and 
was located close to the pylorus, or if there was a scar at the 
duodenal bulb, Billroth II gastrojejunostomy was per-
formed. Billroth II anastomosis was generally preferred 
when tumor invasion extended beyond the subserosa.
Application and termination of CP
The designation of cases to be managed by the CP and 
termination of the CP were determined by the residents in 
charge of the patients. The causes for termination of the CP 
were classified according to four criteria: 1) additional 
medical care (laboratory tests) or workup needed due to 
medical problems (unexpected abdominal pain or dis-
comfort, fever, etc.), 2) postoperative complications (ana-
stomotic leakage, fluid collection, wound problems, in-
testinal obstruction, etc.), 3) non-compliance of the pa-
tients (delayed discharge, etc.), and 4) additional oper-
ations performed during gastrectomy (hysterectomy, etc.).
Statistical analyses
Statistical analyses were performed using SPSS ver. 12.0 
(SPSS Inc., Chicago, IL, USA). The data are presented as 
means ± SD. For validation of significance, the paired t-test 
and the χ
2 test were applied. Data were considered to be 
statistically significant if the probability was less than 5%. 
RESULTS
Patient characteristics
The mean age of the patients was 59.2 ± 12.1, and the 
male to female ratio was 2.1:1. The most frequently per-
formed surgical procedure was radical subtotal gas-
trectomy (476, 75.4%), followed by radical total gas-
trectomy (121, 19.2%), proximal gastrectomy (22, 3.5%), 
and pylorus preserving gastrectomy. A combined multi-Sang-Ho Jeong, et al.
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Table 2. Operative morbidities between the non-CP and CP groups 
EGC AGC
Non-CP CP  group P-value Non-CP  CP  group P-value
Leakage 2 (1.1) 2 (1.8) 0.64   3 (1.4) 2 (1.8)              1.0
Fluid collection 6 (3.2) 6 (5.1) 0.54  25 (11.5) 4 (3.6) 0.02
Wound problem 8 (4.3) 9 (7.6) 0.30  4 (1.8) 4 (3.6) 0.44
Postoperative bleeding 2 (1.1) 1 (0.8)         1.0  1 (0.5) 1 (0.9)              1.0
Ileus 2 (1.1) 5 (4.2) 0.11  5 (2.3) 4 (3.6) 0.49
Stenosis 4 (2.2) 1 (0.8) 0.65  6 (2.8) 2 (1.8) 0.72
Pulmonary problem 4 (2.2) 5 (4.2) 0.31 11 (5.0) 1 (0.9) 0.06
Others 3 (1.6) 3 (2.5) 0.68 13 (6.0) 2 (1.8) 0.10
Total complications 24 (13) 24 (20.3) 0.10   52 (23.9) 18 (16.4) 0.15
Values are presented as number (%).
EGC, early gastric cancer group; AGC, advance gastric cancer group; CP, critical pathway.
Table 1. Patient characteristics
EGC AGC
Non-CP CP P-value Non-CP CP P-value
Age (mean, yr)      59.7      58.2 0.29      59.1    59.3 0.87
Sex Male 131  77 0.31 150 72 0.53
Female   54  41  68 38
Operation name RSG 156 101 0.87 137 82 0.03
RTG   17    8 0.52  71 25 0.07
PG     8    2 0.32    9   3 0.75
PPG     4    7 0.11    1   0          1.0
Combined organ resection 25/185 17/118 0.86 52/218 26/110          1.0
TNM Stage I 185 117 0.39  69 (31.7%) 41 (37.3%) 0.32
Stage II  77 (35.3%) 28 (25.5%) 0.08
Stage III  54 (24.8%) 35 (31.8%) 0.19
Stage IV    0   1 0.38 18 (8.3%) 6 (5.5%) 0.50
EGC, early gastric cancer group; AGC, advance gastric cancer group; CP, critical pathway; RSG, radical subtotal gastrectomy; RTG, radical 
total gastrectomy; PG, proximal gastrectomy; PPG, pylorus preserving gastrectomy; TNM, tumor, node, metastasis.
organ resection was performed on 19% of the patients. 
TNM staging classified 65.3% of the cancers at stage I, fol-
lowed by 16.6% at stage II, 14.4% at stage III, and 4% at 
stage IV.
Comparison of non-CP and CP groups in EGC and AGC 
patients showed no differences between these two groups, 
except for a higher number of subtotal gastrectomies in the 
CP group of AGC patients (Table 1). 
Comparison of morbidity rate and readmission rate between 
non-CP and CP groups in EGC and AGC patients
The overall morbidity rate was 18.7%, and there were no 
significant differences in the morbidity rate between the 
non-CP and CP groups in the EGC and AGC patients (P = 
0.10 and P = 0.15). In surgical complication assessment, flu-
id collection was more frequently noted in the non-CP 
group than in the CP group in AGC patients (P = 0.02), but 
there were no significant differences in other compli-
cations. Additionally, four patients (1.8%) in the non-CP 
group and one patient (0.9%) in the CP group in the AGC 
group required readmission 30 days after surgery, but the 
difference was not statistically significant (P = 0.66). There 
were no mortality cases in either group (Table 2). Critical pathway for gastric cancer
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Table 3. Comparison of the mean length of hospital stay between the non-CP, CP groups
EGC AGC
Non-CP CP P-value Non-CP CP P-value
Hospital stay
Pre-op   3.88   3.16 0.00 4.5   3.63 0.00
Post-op 12.34 11.04 0.38 13.96 12.05 0.06
Total 16.21 14.20 0.14 18.48 15.68 0.01
Hospital cost, \
a)
Pre-op 1,307,558 1,053,341 0.00 1,564,053 1,167,514 0.00
Post-op 6,079,912 6,306,096 0.64 7,237,078 6,745,964 0.27
Total 7,384,470 7,359,437 0.96 8,801,131 7,913,477 0.08
EGC, early gastric cancer group; AGC, advance gastric cancer group; CP, critical pathway; Pre-op, preoperative; Post-op, postoperative.
a)Korean monetary unit.
Table 4. Termination causes of gastrectomy critical pathway (CP)
Cause of CP termination (%)
Need for additional medical care 52
Postoperative complications 24
Additional unexpected operations  9
Patient non-compliance  4
Non-reported or technical errors 12
Fig. 3. Comparison of application rate, completion rates in four 
disease groups. La. Cholecystectomy, laparoscopic cholecystec-
tomy.
Length of hospital stay and cost comparison between non-CP 
and CP groups in EGC and AGC patients
The mean length of preoperative hospital stays were 
significantly different between the EGC and AGC patients 
(P ＜  0.05). The mean length of total hospital stays was 18.4 
days in the non-CP group and 15.6 days in the CP group in 
AGC patients, and this difference was statistically sig-
nificant (P = 0.01). However, there was no difference in the 
mean length of postoperative hospital stays between 
non-CP and CP groups in either EGC patients or AGC pa-
tients (P ＞  0.05).
The postoperative and total cost of hospitalization was 
not statistically different between either of the groups (P 
＞  0.05); however, the mean preoperative costs were sig-
nificantly different (P ＜  0.05, Table 3).
Termination causes of gastrectomy CP
The most common cause of the termination of CP in gas-
trectomy was the need for additional medical care (52%), 
followed by the incidence of postoperative complications 
(24%), performance of additional unexpected operations 
(9%), patient non-compliance (4%), and non-reported or 
technical errors (12%) (Table 4).
Comparison of CP application and completion rate
The application rate of the CP in gastrectomy was 43% 
and the completion rate was 19%. The CP was applied in 
cases of mastectomy, thyroidectomy and laparoscopic 
cholecystectomy at rates of 99%, 98% and 53%, respec-
tively. The completion rates for CP in cases of mastectomy, 
thyroidectomy and laparoscopic cholecystectomy were 
58%, 45% and 53%, respectively (Fig. 3). 
DISCUSSION
Hospitals are under pressure to reduce costs while Sang-Ho Jeong, et al.
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maintaining or increasing the quality of care. Develop-
ment of the CP began with the introduction of diag-
nosis-related groups and the prospective payment system 
in the United States, which was implemented to improve 
hospital management through measures such as short-
ening the length of hospital stay, reducing the costs of hos-
pitalization, and increasing the efficiency of nursing care 
[17].
Introduction of the CP helped streamline the post-
operative care of surgical patients and reduced the cost 
and length of hospital stay for patients undergoing gen-
eral surgical procedures [6,17,18]. However, studies have 
drawn conflicting conclusions on the efficacy of the CP. In 
some studies, the success of critical pathways may reflect 
patient selection bias, and may be the result of clinical 
‘cherry picking’ rather than the effect of pathway manage-
ment [19]. A study of 32 Connecticut hospitals [20], as well 
as other studies of medical and surgical pathways [1,21], 
have reported that critical pathways do not reduce the 
length of hospital stay more than the pre-pathway secular 
trends in comparable local hospitals with similarly man-
aged care pressures. The results of the present study show 
that, while the mean preoperative hospital stay decreased 
in EGC and AGC patients, there were no differences in the 
length of postoperative hospital stay and hospital cost. 
The study also showed that a preoperative workup at an 
outpatient clinic contributed significantly to shortening 
the length of preoperative hospital stay and reducing the 
hospital cost. Thus, utilizing preoperative examination 
and consultation in outpatient clinics would decrease the 
length of hospital stay and cost without the necessity of 
implementing the CP for the treatment of gastric cancer.
The completion rate of the CP for gastrectomy patients 
was only 19%, but the rates for patients undergoing mas-
tectomy, thyroidectomy and laparoscopic cholecystec-
tomy were 45 to 58%. We conclude that CP is more effec-
tive in patients with benign disease or undergoing non- 
bowel surgery than in those undergoing gastrectomy. This 
is possibly due to gastrectomy being a major operation of-
ten associated with postoperative hemodynamic changes. 
In the present study, the most common causes of the termi-
nation of CP in gastrectomy patients were the need for ad-
ditional medical care and the development of post-
operative complications. Most upper gastrointestinal sur-
geries often require additional medical care and incur 
more postoperative complications compared to benign 
disease or non-bowel surgery. Therefore, it is possible to 
encourage the introduction of the CP in upper gastro-
intestinal surgery with the acceptance of an additional re-
peat orders and the allowance for frequent additional or-
ders (ex, complete blood cell count, electrolyte, Chest 
X-ray) in limited periods. Another cause of no differences 
of hospital stay is that it is same hospital course between 
CP group and non-CP group after diet. In the absence of 
complications after the ingestion of water, patients were 
started on a semi-fluid diet in both groups. The patients 
were discharged from the hospital after two days of 
semi-fluid diet and one day of a soft brand diet. Therefore, 
our results indicate that the introduction of the CP is not 
beneficial for the treatment of conditions that require up-
per gastrointestinal surgery. 
We conclude that the introduction of the CP in cases of 
gastrectomy is unnecessary. We recommend increased uti-
lization of preoperative examination and operative sur-
gery consultations for decreasing the length of hospital 
stay and the associated costs of hospitalization. 
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